樂觀
$605.58
情境價格
$452.290
+8.594 (+1.90%)收盤時
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
Intuitive Surgical Inc is a good buy right now due to its recent earnings beat with an EPS of $2.53, exceeding estimates by 18.78%, and a forward P/E ratio of 33.33, indicating growth potential at a reasonable valuation. The stock has shown a positive momentum with a 5-day change of +6.00% and a current RSI of 76.78, suggesting strong buying interest. However, the main risk is the recent 10% drop in share price following disappointing earnings, which could indicate market volatility ahead.
BTIG
$454
2026-10-12
BTIG
2026-10-12
目標價
$454
Barclays
$485
2026-10-06
Barclays
2026-10-06
目標價
$485
Oppenheimer
—
2026-08-12
Oppenheimer
2026-08-12
目標價
—
HSBC
$391
2026-07-30
HSBC
2026-07-30
目標價
$391
UBS
$500
2026-07-28
UBS
2026-07-28
目標價
$500
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。
Meta, SpaceX, and Tesla's Heavy AI Investments

Cathie Wood's Daily Transparency in ETF Investments

Midday Trading Highlights for Various Companies

Intuitive Surgical Announces Price Cuts to Expand Market Adoption

Intuitive Surgical Exceeds Q3 Revenue and Earnings Estimates
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).
Intuitive Surgical Inc is a good buy right now due to its recent earnings beat with an EPS of $2.53, exceeding estimates by 18.78%, and a forward P/E ratio of 33.33, indicating growth potential at a reasonable valuation. The stock has shown a positive momentum with a 5-day change of +6.00% and a current RSI of 76.78, suggesting strong buying interest. However, the main risk is the recent 10% drop in share price following disappointing earnings, which could indicate market volatility ahead.
17 analysts cover ISRG: 11 rate it Buy, 5 Hold and 1 Sell. The average price target is 637.32.


$ISRG "Trade Idea 2: Buy the October 23 Expiry 437.50/452.50 Call Spread ($6.60) and sell the October 23 Expiry 410 Put for 30 cents." The call spread looks to be a bust; may need to roll puts down and out.
展開

$ISRG Barclays initiates coverage with an Overweight rating and a $485 target price.
展開
$ISRG The long-term technical setup for this med device stock is excellent.
展開本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。